{"id":"tp-53843","type":"article-newspaper","title":"Maze Therapeutics Posts $0.79 Q3 GAAP Loss Per Share as R&D Costs Rise","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/53843","datePublished":"2026-11-11T10:52:26.000Z","dateModified":"2026-11-11T10:52:26.000Z","language":"en","abstract":"Net loss reached $48 million. Cash, cash equivalents and marketable securities totaled $477 million on Sept. 30, 2026.","section":"Business","references":[]}